A citation-based method for searching scientific literature

Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias, Deolinda Pereira, Pauline Wimberger, Ana Oaknin, Mansoor Raza Mirza, Philippe Follana, David Bollag, Isabelle Ray-Coquard. J Clin Oncol 2014
Times Cited: 766







List of co-cited articles
512 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
Bradley J Monk, Andrés Poveda, Ignace Vergote, Francesco Raspagliesi, Keiichi Fujiwara, Duk-Soo Bae, Ana Oaknin, Isabelle Ray-Coquard, Diane M Provencher, Beth Y Karlan,[...]. Gynecol Oncol 2016
48
6

Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.
Eric Pujade-Lauraine, Keiichi Fujiwara, Samuel S Dychter, Geeta Devgan, Bradley J Monk. Future Oncol 2018
39
7

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
3

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Jung-Min Lee, Ashley Cimino-Mathews, Cody J Peer, Alexandra Zimmer, Stanley Lipkowitz, Christina M Annunziata, Liang Cao, Maria I Harrell, Elizabeth M Swisher, Nicole Houston,[...]. J Clin Oncol 2017
137
3

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
3

Immunotherapy in Ovarian Cancer: Are We There Yet?
Lana E Kandalaft, Kunle Odunsi, George Coukos. J Clin Oncol 2019
32
9

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Panagiotis A Konstantinopoulos, Barbara Norquist, Christina Lacchetti, Deborah Armstrong, Rachel N Grisham, Paul J Goodfellow, Elise C Kohn, Douglas A Levine, Joyce F Liu, Karen H Lu,[...]. J Clin Oncol 2020
53
5

Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Ahmed Elattar, Andrew Bryant, Brett A Winter-Roach, Mohamed Hatem, Raj Naik. Cochrane Database Syst Rev 2011
202
3

Recent progress in the diagnosis and treatment of ovarian cancer.
Danijela Jelovac, Deborah K Armstrong. CA Cancer J Clin 2011
458
3

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
Neil Senzer, Minal Barve, Joseph Kuhn, Anton Melnyk, Peter Beitsch, Martin Lazar, Samuel Lifshitz, Mitchell Magee, Jonathan Oh, Susan W Mill,[...]. Mol Ther 2012
106
3

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
Evanthia Galanis, Lynn C Hartmann, William A Cliby, Harry J Long, Prema P Peethambaram, Brigitte A Barrette, Judith S Kaur, Paul J Haluska, Ileana Aderca, Paula J Zollman,[...]. Cancer Res 2010
190
3

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Jonathan Oh, Minal Barve, Carolyn M Matthews, E Colin Koon, Thomas P Heffernan, Bruce Fine, Elizabeth Grosen, Melanie K Bergman, Evelyn L Fleming, Leslie R DeMars,[...]. Gynecol Oncol 2016
42
7

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J O'Connor, Tony W Ho, Jane D Robertson, Jerry S Lanchbury,[...]. Br J Cancer 2018
70
4

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, John K Chan, Minal A Barve, Jonathan Oh, Devansu Tewari, Peter C Morris, Erin E Stevens, Justin N Bottsford-Miller,[...]. Lancet Oncol 2020
14
21

PARP inhibitors in ovarian cancer.
Elisena Franzese, Sara Centonze, Anna Diana, Francesca Carlino, Luigi Pio Guerrera, Marilena Di Napoli, Ferdinando De Vita, Sandro Pignata, Fortunato Ciardiello, Michele Orditura. Cancer Treat Rev 2019
78
3

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Junzo Hamanishi, Masaki Mandai, Masashi Iwasaki, Taku Okazaki, Yoshimasa Tanaka, Ken Yamaguchi, Toshihiro Higuchi, Haruhiko Yagi, Kenji Takakura, Nagahiro Minato,[...]. Proc Natl Acad Sci U S A 2007
989
3


Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, Anna V Tinker, Nelson N H Teng, Maria I Harrell, Michael J Kuiper, Gwo-Yaw Ho, Holly Barker, Maria Jasin,[...]. Cancer Discov 2017
141
3

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Kevin K Lin, Maria I Harrell, Amit M Oza, Ana Oaknin, Isabelle Ray-Coquard, Anna V Tinker, Elena Helman, Marc R Radke, Carmen Say, Lan-Thanh Vo,[...]. Cancer Discov 2019
100
3

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Alexandra S Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C Kohn, Christina M Annunziata, Stanley Lipkowitz, Jane B Trepel,[...]. J Immunother Cancer 2019
40
7

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
876
3

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Jung-Min Lee, Jayakumar Nair, Alexandra Zimmer, Stanley Lipkowitz, Christina M Annunziata, Maria J Merino, Elizabeth M Swisher, Maria I Harrell, Jane B Trepel, Min-Jung Lee,[...]. Lancet Oncol 2018
80
3

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Stephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, Swati Garg, Michael Cabanero, Gina Mantia-Smaldone, Alexander B Olawaiye, Susan L Ellard, Johanne I Weberpals, Andrea E Wahner Hendrickson,[...]. Lancet 2021
16
18

Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
Kathryn F McGonigle, Howard G Muntz, Jacqueline Vuky, Pamela J Paley, Dan S Veljovich, Benjamin E Greer, Barbara A Goff, Heidi J Gray, Thomas W Malpass. Cancer 2011
50
6

Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
Chun-Yan Lan, Yin Wang, Ying Xiong, Jun-Dong Li, Jing-Xian Shen, Yan-Fang Li, Min Zheng, Yan-Na Zhang, Yan-Ling Feng, Qing Liu,[...]. Lancet Oncol 2018
67
4

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg,[...]. Lancet Oncol 2013
720
3

Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Roman Rouzier, Sébastien Gouy, Frédéric Selle, Eric Lambaudie, Anne Floquet, Virginie Fourchotte, Christophe Pomel, Pierre-Emmanuel Colombo, Elsa Kalbacher, Sandrine Martin-Francoise,[...]. Eur J Cancer 2017
41
7

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
767
3

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Richard W Tothill, Anna V Tinker, Joshy George, Robert Brown, Stephen B Fox, Stephen Lade, Daryl S Johnson, Melanie K Trivett, Dariush Etemadmoghadam, Bianca Locandro,[...]. Clin Cancer Res 2008
904
3

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Markus M Heiss, Pawel Murawa, Piotr Koralewski, Elzbieta Kutarska, Olena O Kolesnik, Vladimir V Ivanchenko, Alexander S Dudnichenko, Birute Aleknaviciene, Arturas Razbadauskas, Martin Gore,[...]. Int J Cancer 2010
301
3

Second-line lenvatinib in patients with recurrent endometrial cancer.
Ignace Vergote, Matthew A Powell, Michael G Teneriello, David S Miller, Agustin A Garcia, Olga N Mikheeva, Mariusz Bidzinski, Cristina Ligia Cebotaru, Corina E Dutcus, Min Ren,[...]. Gynecol Oncol 2020
11
27

PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
R Wendel Naumann, Robert L Coleman, Robert A Burger, Edward A Sausville, Elzbieta Kutarska, Sharad A Ghamande, Nashat Y Gabrail, Stephen E Depasquale, Elzbieta Nowara, Lucy Gilbert,[...]. J Clin Oncol 2013
132
3

Combinations of Bevacizumab With Cancer Immunotherapy.
Daniel S Chen, Herbert Hurwitz. Cancer J 2018
68
4

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
M Markman, R Rothman, T Hakes, B Reichman, W Hoskins, S Rubin, W Jones, L Almadrones, J L Lewis. J Clin Oncol 1991
652
3

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Michael Friedlander, Ursula Matulonis, Charlie Gourley, Andreas du Bois, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Br J Cancer 2018
68
4


Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
Eric Pujade-Lauraine, Susana Banerjee, Sandro Pignata. J Clin Oncol 2019
26
11

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.
Fiona Collinson, Michelle Hutchinson, Rachel A Craven, David A Cairns, Alexandre Zougman, Tobias C Wind, Narinder Gahir, Michael P Messenger, Sharon Jackson, Douglas Thompson,[...]. Clin Cancer Res 2013
49
6

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
J P Neijt, S A Engelholm, M K Tuxen, P G Sorensen, M Hansen, C Sessa, C A de Swart, F R Hirsch, B Lund, H C van Houwelingen. J Clin Oncol 2000
331
3

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
Stergios Boussios, Peeter Karihtala, Michele Moschetta, Afroditi Karathanasi, Agne Sadauskaite, Elie Rassy, Nicholas Pavlidis. Diagnostics (Basel) 2019
57
5

Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
Xavier Paoletti, Liz-Anne Lewsley, Gennaro Daniele, Adrian Cook, Nozomu Yanaihara, Anna Tinker, Gunnar Kristensen, Petronella B Ottevanger, Gerasimos Aravantinos, Austin Miller,[...]. JAMA Netw Open 2020
11
27

Cancer of the ovary.
Stephen A Cannistra. N Engl J Med 2004
3

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.
Katy Milne, Martin Köbel, Steven E Kalloger, Rebecca O Barnes, Dongxia Gao, C Blake Gilks, Peter H Watson, Brad H Nelson. PLoS One 2009
261
3

Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman. Immunity 2013
3

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Tomoe Higuchi, Dallas B Flies, Nicole A Marjon, Gina Mantia-Smaldone, Lukas Ronner, Phyllis A Gimotty, Sarah F Adams. Cancer Immunol Res 2015
154
3


Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, Ciro Gallo, Eric Pujade-Lauraine, Sabino De Placido, Alessandra Bologna, Beatrice Weber, Francesco Raspagliesi, Pierluigi Benedetti Panici,[...]. Lancet Oncol 2014
206
3

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
3

The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.
Giuseppe Scaletta, Francesco Plotti, Daniela Luvero, Stella Capriglione, Roberto Montera, Andrea Miranda, Salvatore Lopez, Corrado Terranova, Carlo De Cicco Nardone, Roberto Angioli. Expert Rev Anticancer Ther 2017
54
5

Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Russell Vang, Douglas A Levine, Robert A Soslow, Charles Zaloudek, Ie-Ming Shih, Robert J Kurman. Int J Gynecol Pathol 2016
83
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.